体检人群非酒精性脂肪性肝病检出率及其危险因素分析*

doi:10.3969/j.issn.1672-5069.2023.01.010

摘要/Abstract

摘要： 目的分析体检人群非酒精性脂肪性肝病(NAFLD)流行率及其危险因素。方法 2018年1月～2020年1月我院体检中心接受体检人群1742例,排除干扰因素后,纳入485例,经超声检查诊断NAFLD者78例,非NAFLD者407例。使用CT扫描仪测量腹腔内脏脂肪面积(VAT)和腹壁皮下脂肪面积(SAT)。检测空腹血糖(FPG)等生化指标。应用单因素和多因素Logistic回归分析NAFLD发病的影响因素。结果 NAFLD组高血压、糖尿病和血脂血症患病率分别为29.5%、35.9%和51.3%,显著高于非NAFLD组(分别为18.7%、23.8%和23.6%,P<0.05),BMI、腰围和臀围分别为(25.1±1.)kg/m²、(90.4±6.3)cm和(101.3±8.4)cm,显著高于非NAFLD组【分别为(22.4±1.1)kg/m²、(81.6±5.7)cm和(95.7±6.2)cm,P<0.05】;血清TG、LDL-C和VAT分别为(2.9±0.3)mmol/L、(3.7±0.4)mmol/L和(146.3±12.1)cm²,显著高于非NAFLD组【分别为(1.6±0.2)mmol/L、(3.1±0.2)mmol/L和(70.5±4.6)cm²,P<0.05】;血清ALT、FPG和UA水平分别为(56.6±11.7)u/L、(5.8±0.7)mmol/L和(387.8±36.3)μmol/L,均显著高于非NAFLD组【分别为(32.4±3.1)u/L、(5.1±0.4)mmol/L和(313.6±51.4)μmol/L,P<0.05】;多因素回归分析结果显示,BMI增高、VAT增大、合并高血压、血清TG、LDL-C、ALT和UA水平升高是患NAFLD的独立风险因素,而血清HDL-C水平升高则是NAFLD的保护因素。结论体检人群NAFLD检查率较高,而一些体质、血清和影像学检查指标可以提示疾病的存在而需要进一步明确诊断和干预。

关键词: 非酒精性脂肪性肝病, 腹腔内脏脂肪面积, 危险因素, 多因素分析, 体检人群

Abstract: Objective The aim of this study was to analyze the risk factors of non-alcoholic fatty liver diseases (NAFLD) in physical examination individuals. Methods 1742 persons received physical examination in our hospital between January 2018 and January 2020, and 485 individuals were eligible for this study based on inclusion and exclusion criteria. The NAFLD was found by ultrasonography in 78 cases and not in 407 cases. The visceral adipose tissue (VAT)was obtained by CT scan, and fasting plasma glucose (FPG) and other common blood parameters were assayed. The risk factors for NAFLD was analyzed by univariate and multivariate Logistic regression. Results The incidences of concomitant blood hypertension, diabetes and hyperlipidemia in patients with NAFLD were 29.5%, 35.9% and 51.3%, much higher than 18.7%, 23.8% and 23.6% (P<0.05), the body mass index, waist and hip circumference were (25.1±1.)kg/m², (90.4±6.3)cm and (101.3±8.4)cm, much higher than [(22.4±1.1)kg/m², (81.6±5.7)cm and (95.7±6.2)cm, respectively, P<0.05] in persons without NAFLD; serum TG, LDL-C and VAT were (2.9±0.3)mmol/L,(3.7±0.4)mmol/L and (146.3±12.1)cm², significantly higher than [(1.6±0.2)mmol/L, (3.1±0.2)mmol/L and (70.5±4.6)cm², respectively, P<0.05] in persons without NAFLD; serum ALT, FPG and UA levels were (56.6±11.7)u/L, (5.8±0.7)mmol/L and (387.8±36.3)μmol/L, all significantly higher than [(32.4±3.1)u/L, (5.1±0.4)mmol/L and (313.6±51.4)μmol/L, respectively, P<0.05] in persons without NAFLD; the multivariate Logistic regression analysis showed that the increased BMI, elevated VAT, concomitant blood hypertension, and elevated serum TG, LDL-C, ALT and UA levels were all the independent risk factors, while the increased serum HDL-C level was the protective factor for the existence of NAFLD. Conclusion The prevalence of NAFLD in physical examination individuals is relative high, and some increased body health, blood and imaging parameters hints its existence, and warrants further check-up.

Key words: Non-alcoholic fatty liver diseases, Visceral adipose tissue, Risk factors, Logistic analysis, Physical examination

徐伟强, 刘淑萍, 李潇萌. 体检人群非酒精性脂肪性肝病检出率及其危险因素分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 35-38.

Xu Weiqiang, Liu Shuping, Li Xiaomeng. Risk factors of non-alcoholic fatty liver diseases in physical examination individuals[J]. Journal of Practical Hepatology, 2023, 26(1): 35-38.

参考文献

[1] Taheri H, Malek M, Ismail-Beigi F,et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther, 2020,37(11):4697-4708.
[2] D'Abbondanza M, Ministrini S, Pucci G,et al. Very low-carbohydrate ketogenic diet for the treatment of severe obesity and associated non-alcoholic fatty liver disease: The role of sex differences. Nutrients, 2020,12(9):2748.
[3] 柴颖,郭宁,么焕新,等. 幽门螺杆菌根除治疗对非酒精性脂肪性肝病脂代谢及胰岛素抵抗的影响. 中华医院感染学杂志,2021,31(9):1319-1323.
[4] Esmail VAW, Mohammed MO, Al-Nimer MSM. Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. Arab J Gastroenterol, 2021,22(1):1-5.
[5] Craven L, Rahman A, Nair Parvathy S,et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial. Am J Gastroenterol, 2020,115(7):1055-1065.
[6] Herath HMM, Kodikara I, Weerarathna TP,et al. Prevalence and associations of non-alcoholic fatty liver disease (NAFLD) in Sri Lankan patients with type 2 diabetes: A single center study. Diabetes Metab Syndr, 2019,13(1):246-250.
[7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[8] Newsome PN, Buchholtz K, Cusi K,et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med, 2021,384(12):1113-1124.
[9] 柴颖,郭宁,么焕新,等. 幽门螺杆菌根除治疗对非酒精性脂肪性肝病脂代谢及胰岛素抵抗的影响. 中华医院感染学杂志,2021,31(9):1319-1323.
[10] Smith GI, Shankaran M, Yoshino M,et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest, 2020,130(3):1453-1460.
[11] Newsome PN, Sasso M, Deeks JJ,et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol, 2020,5(4):362-373.
[12] Kuchay MS, Krishan S, Mishra SK,et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia, 2020,63(11):2434-2445.
[13] Chen Y, Feng R, Yang X,et al. Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: a randomized controlled trial. Am J Clin Nutr, 2019,109(6):1611-1619.
[14] Aso Y, Kato K, Sakurai S,et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract, 2019,73(5):e13335.
[15] Schübel R, Nonnenmacher T, Sookthai D, et al. Similar weight loss induces greater improvements in insulin sensitivity and liver function among individuals with NAFLD compared to individuals without NAFLD. Nutrients, 2019,11(3):544.
[16] Babu AF, Csader S, Männistö V,et al. Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool. Sci Rep, 2022,12(1):6485.
[17] 古丽斯亚·海力力,姚华,王淑霞,等. 乌鲁木齐市某区全民体检人群代谢综合征组分聚集性与非酒精性脂肪肝关系. 中华疾病控制杂志,2019,23(11):1358-1363.
[18] Loomba R, Noureddin M, Kowdley KV,et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology, 2021,73(2):625-643.
[19] Stahlschmidt FL, Tafarel JR, Menini-Stahlschmidt CM,et al. Hepatorenal index for grading liver steatosis with concomitant fibrosis. PLoS One, 2021,16(2):e0246837.
[20] Goodarzi R, Jafarirad S, Mohammadtaghvaei N,et al. The effect of pomegranate extract on anthropometric indices, serum lipids, glycemic indicators, and blood pressure in patients with nonalcoholic fatty liver disease: A randomized double-blind clinical trial. Phytother Res, 2021,35(10):5871-5882.

体检人群非酒精性脂肪性肝病检出率及其危险因素分析^*

Risk factors of non-alcoholic fatty liver diseases in physical examination individuals

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄淡霞, 招志辉, 萧月兴, 何艳青. 小檗碱通过调节肠道菌群改善高脂饮食诱导的非酒精性脂肪性肝病大鼠肝组织炎症实验研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 23-26.
[2]	陈凤莲, 朱青蓝, 朱伶俐, 陈国飞. 非酒精性脂肪性肝病患者外周血恒定自然杀伤T细胞和CD4⁺/CD8⁺T细胞活化差异研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 31-34.
[3]	陈怡, 朱友, 周希乔. 甲状腺激素与非酒精性脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2023, 26(1): 145-148.
[4]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.
[5]	孙峥, 王笑烨, 袁景, 梁丽. 达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 796-799.
[6]	蔡勇, 李璟, 欧琴. 2型糖尿病合并非酒精性脂肪性肝病患者血清网膜素、视黄醇结合蛋白4和Ⅰ型原胶原氨基端前肽水平及意义分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 800-803.
[7]	孙凌, 杭玮, 邓国忠. 二甲双胍联合吡格列酮治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 804-807.
[8]	王晓华, 曾雅琳, 郭萃蓉. 非酒精性脂肪性肝病进展性肝纤维化患者空腹血糖受损和胰岛素抵抗调查^*[J]. 实用肝脏病杂志, 2022, 25(6): 812-815.
[9]	樊叶, 张喜梅, 张岩. 非酒精性脂肪性肝病患者血清胱抑素C、脂蛋白α和nesfatin-1水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(6): 816-819.
[10]	沈亦亮, 沈冬元, 陈永莹, 江凯, 朱逸明, 葛尚. 肝硬化患者肝内LR-3类结节恶变风险评估及预测模型的建立^*[J]. 实用肝脏病杂志, 2022, 25(6): 836-839.
[11]	郑希彦, 杜飞, 林志群, 李瑞曦, 周正, 张广权, 周红, 何方平, 史宪杰. 肝细胞癌进展:代谢综合征相关危险因素研究[J]. 实用肝脏病杂志, 2022, 25(6): 877-880.
[12]	曾婷, 雷向阳, 白晓苏. 氧化苦参碱对非酒精性脂肪性肝病大鼠肝脏保护作用研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 624-627.
[13]	刘彦彤, 姚杨, 卢博. 荷叶调脂疏肝汤对非酒精性脂肪性肝病患者脂代谢的影响研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 657-660.
[14]	奚佳颖, 汤佳美, 刘玲玉, 王韦. 超声三维斑点追踪技术评价非酒精性脂肪性肝病合并2型糖尿病患者左心功能研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 661-664.
[15]	潘飞, 寿涓, 张冬青. 不同他汀类药物治疗非酒精性脂肪性肝病合并高脂血症患者效果分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 665-668.